OBJECTIVE: Rheumatic diseases cause significant morbidity within American Indian populations. Clinical disease presentations, as well as historically associated autoantibodies, are not always useful in making a rapid diagnosis or assessing prognosis. The purpose of our study was to identify autoantibody associations among Oklahoma tribal populations with rheumatic disease. METHODS: Oklahoma tribal members (110 patients with rheumatic disease and 110 controls) were enrolled at tribal-based clinics. Patients with rheumatic disease (suspected or confirmed diagnosis) were assessed by a rheumatologist for clinical features, disease criteria, and activity measures. Blood samples were collected and tested for common rheumatic disease autoantibodies [antinuclear antibody (ANA), anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), anti-Ro, anti-La, anti-Sm, anti-nRNP, anti-ribosomal P, anti-dsDNA, and anticardiolipins]. RESULTS: In patients with suspected systemic rheumatic diseases, 72% satisfied American College of Rheumatology classification criteria: 40 (36%) had rheumatoid arthritis (RA), 16 (15%) systemic lupus erythematosus, 8 (7%) scleroderma, 8 (7%) osteoarthritis, 4 (4%) fibromyalgia, 2 (2%) seronegative spondyloarthropathy, 1 Sjögren's syndrome, and 1 sarcoidosis. Compared to controls, RA patient sera were more likely to contain anti-CCP (55% vs 2%; p < 0.001) or RF IgM antibodies (57% vs 10%; p < 0.001); however, the difference was greater for anti-CCP. Anti-CCP positivity conferred higher disease activity scores (DAS28 5.6 vs 4.45; p = 0.021) while RF positivity did not (DAS28 5.36 vs 4.64; p = 0.15). Anticardiolipin antibodies (25% of rheumatic disease patients vs 10% of controls; p = 0.0022) and ANA (63% vs 21%; p < 0.0001) were more common in rheumatic disease patients. CONCLUSION: Anti-CCP may serve as a more specific RA biomarker in American Indian patients, while the clinical significance of increased frequency of anticardiolipin antibodies needs further evaluation.
OBJECTIVE:Rheumatic diseases cause significant morbidity within American Indian populations. Clinical disease presentations, as well as historically associated autoantibodies, are not always useful in making a rapid diagnosis or assessing prognosis. The purpose of our study was to identify autoantibody associations among Oklahoma tribal populations with rheumatic disease. METHODS:Oklahoma tribal members (110 patients with rheumatic disease and 110 controls) were enrolled at tribal-based clinics. Patients with rheumatic disease (suspected or confirmed diagnosis) were assessed by a rheumatologist for clinical features, disease criteria, and activity measures. Blood samples were collected and tested for common rheumatic disease autoantibodies [antinuclear antibody (ANA), anti-cyclic citrullinated peptide antibodies (anti-CCP), rheumatoid factor (RF), anti-Ro, anti-La, anti-Sm, anti-nRNP, anti-ribosomal P, anti-dsDNA, and anticardiolipins]. RESULTS: In patients with suspected systemic rheumatic diseases, 72% satisfied American College of Rheumatology classification criteria: 40 (36%) had rheumatoid arthritis (RA), 16 (15%) systemic lupus erythematosus, 8 (7%) scleroderma, 8 (7%) osteoarthritis, 4 (4%) fibromyalgia, 2 (2%) seronegative spondyloarthropathy, 1 Sjögren's syndrome, and 1 sarcoidosis. Compared to controls, RApatient sera were more likely to contain anti-CCP (55% vs 2%; p < 0.001) or RF IgM antibodies (57% vs 10%; p < 0.001); however, the difference was greater for anti-CCP. Anti-CCP positivity conferred higher disease activity scores (DAS28 5.6 vs 4.45; p = 0.021) while RF positivity did not (DAS28 5.36 vs 4.64; p = 0.15). Anticardiolipin antibodies (25% of rheumatic diseasepatients vs 10% of controls; p = 0.0022) and ANA (63% vs 21%; p < 0.0001) were more common in rheumatic diseasepatients. CONCLUSION: Anti-CCP may serve as a more specific RA biomarker in American Indian patients, while the clinical significance of increased frequency of anticardiolipin antibodies needs further evaluation.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: P J Clements; E L Hurwitz; W K Wong; J R Seibold; M Mayes; B White; F Wigley; M Weisman; W Barr; L Moreland; T A Medsger; V D Steen; R W Martin; D Collier; A Weinstein; E Lally; J Varga; S R Weiner; B Andrews; M Abeles; D E Furst Journal: Arthritis Rheum Date: 2000-11
Authors: R Hal Scofield; Rohan Sharma; Nathan Pezant; Jennifer A Kelly; Lida Radfar; David M Lewis; C Erick Kaufman; Sarah Cioli; Judy Harris; Kiely Grundahl; Nelson L Rhodus; Daniel J Wallace; Michael H Weisman; Swamy Venuturupalli; Michael T Brennan; Kristi A Koelsch; Christopher J Lessard; Courtney G Montgomery; Kathy L Sivils; Astrid Rasmussen Journal: Arthritis Care Res (Hoboken) Date: 2020-07-05 Impact factor: 4.794
Authors: Samantha Slight-Webb; Carla J Guthridge; Joseph Kheir; Hua Chen; Ly Tran; Tim Gross; Virginia Roberts; Sohail Khan; Michael Peercy; Bobby Saunkeah; Joel M Guthridge; Judith A James Journal: Arthritis Care Res (Hoboken) Date: 2021-10-01 Impact factor: 4.794
Authors: Elizabeth D Ferucci; Janet M Johnston; Jasmine R Gaddy; Lisa Sumner; James O Posever; Tammy L Choromanski; Caroline Gordon; S Sam Lim; Charles G Helmick Journal: Arthritis Rheumatol Date: 2014-09 Impact factor: 10.995
Authors: Joseph M Kheir; Carla J Guthridge; Jonathon R Johnston; Lucas J Adams; Astrid Rasmussen; Timothy F Gross; Melissa E Munroe; Rebecka L Bourn; Kathy L Sivils; Joel M Guthridge; Michael H Weisman; Daniel J Wallace; Juan-Manuel Anaya; Adriana Rojas Villarraga; James N Jarvis; John B Harley; Judith A James Journal: Lupus Sci Med Date: 2018-02-27